ClinicalTrials.Veeva

Menu

Pre-approval Single-patient Expanded Access for Elranatamab (PF-06863135)

Pfizer logo

Pfizer

Status

Conditions

Multiple Myeloma

Treatments

Drug: Elranatamab

Study type

Expanded Access

Funder types

Industry

Identifiers

NCT05238311
C107
NCT05238311 (Registry Identifier)

Details and patient eligibility

About

Provide pre-approval single-patient Expanded Access (Compassionate Use) of elranatamab for patients with relapsed/refractory multiple myeloma

Full description

In Expanded Access, treating physicians are the Sponsors

Expanded Access requests from treating physicians should be directed to www.pfizercares.com Availability will depend on location.

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Must have relapsed/refractory multiple myeloma (RRMM) and be refractory to at least one immunomodulatory drug, one proteasome inhibitor and one anti-CD38 antibody. Must have evidence of disease progression after last therapy. Must have exhausted all available treatment options accessible as local standard of care and not be eligible for participation in any ongoing clinical trial. Additional eligibility criteria may be required.

Trial contacts and locations

0

Loading...

Central trial contact

PfizerCares

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems